Vestibular disorder

disease
On this page

Also known as disease of vestibular labyrinthdisease of vestibular systemdisease or disorder of vestibular labyrinthdisorder of vestibular labyrinthdisorder of vestibular systemvestibular labyrinth diseasevestibular labyrinth disease or disordervestibular system disease

Summary

Vestibular disorder (MONDO:0002643) is a disease with 16 GWAS associations across 19 studies and 79 clinical trials. Top therapeutic interventions include betahistine and indoprofen. A subtype of inner ear disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 16
  • Clinical trials: 79

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namevestibular disorder
Mondo IDMONDO:0002643
EFOEFO:0009691
MeSHD015837
DOIDDOID:3426
UMLSC0042594
MedGen12079
Anatomy (UBERON)UBERON:0001862
Is cancer (heuristic)no

Also known as: disease of vestibular labyrinth · disease of vestibular system · disease or disorder of vestibular labyrinth · disorder of vestibular labyrinth · disorder of vestibular system · vestibular labyrinth disease · vestibular labyrinth disease or disorder · vestibular system disease

Data availability: 16 GWAS associations (19 studies).

Disease family

This is a subtype of inner ear disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorderinner ear disordervestibular disorder

Related subtypes (14): bilateral hyperactive labyrinth, labyrinthine bilateral reactive loss, labyrinthitis, labyrinthine unilateral reactive loss, unilateral hyperactive labyrinth, cochlear disorder, bilateral hypoactive labyrinth, unilateral hypoactive labyrinth, otosclerosis, motion sickness, X-linked mixed hearing loss with perilymphatic gusher, autoimmune inner ear disease, enlarged vestibular aqueduct syndrome, inner ear neoplasm

Subtypes (1): peripheral vertigo

Genetics & variants

GWAS landscape

16 GWAS associations across 19 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs108620894e-30OTOGLG0.22
rs118826519e-30LINC01224C0.13
chr19:235402172e-22T0.13
chr19:233669398e-20C0.13
rs29800972e-12TMEM128 - LYARC0.08
chr12:803056956e-12T0.16
chr4:42519147e-12A0.09
chr4:42543202e-11T0.08
chr11:175675992e-10G0.11
chr6:1332919361e-08AT0.07
chr11:1211186262e-08G0.07
chr2:2312111373e-08T0.09
chr5:1400452883e-08T2.08
chr4:1765776964e-08C2.36
rs80191615e-07MIA2?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90475905Verma A202416,493416,520Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473491UK Biobank Whole-Genome Sequencing Consortium202512,508445,932Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667954UK Biobank Whole-Genome Sequencing Consortium202512,508445,932Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90436044Zhou W20186,134402,827Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90652153Liu TY20254,759201,629Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90077834Backman JD20213,950327,804Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081820Backman JD20213,950327,804Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90077835Backman JD20213,505325,547Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081821Backman JD20213,505325,547Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90079943Backman JD20213,343378,017Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic14

MAF distribution

BucketVariants
common (>=0.05)6
low_freq (0.01-0.05)0
rare (<0.01)0
unknown9

Functional consequences

ConsequenceCount
unknown11
intron_variant2
missense_variant1
intergenic_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs108620891280305695G>T0.081missense_variantOTOGL4e-30Tier 1: coding
rs118826511923408594C>G,T0.302intron_variantLINC012249e-30Tier 4: intronic/intergenic
chr19:235402170.2122e-22Tier 4: intronic/intergenic
chr19:233669398e-20Tier 4: intronic/intergenic
rs298009744251914C>A,G0.396intergenic_variantTMEM128 - LYAR2e-12Tier 4: intronic/intergenic
chr12:803056956e-12Tier 4: intronic/intergenic
chr4:42519147e-12Tier 4: intronic/intergenic
chr4:42543200.3482e-11Tier 4: intronic/intergenic
chr11:175675992e-10Tier 4: intronic/intergenic
chr6:1332919361e-08Tier 4: intronic/intergenic
chr11:1211186262e-08Tier 4: intronic/intergenic
chr2:2312111373e-08Tier 4: intronic/intergenic
chr5:1400452883e-08Tier 4: intronic/intergenic
chr4:1765776964e-08Tier 4: intronic/intergenic
rs80191611439319478G>A,C,T0.05intron_variantMIA25e-07Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 79.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified79

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03799991Not specifiedRECRUITINGVestibular Therapy in Alzheimer’s Disease
NCT04685746Not specifiedRECRUITINGBALANCED GROWTH: The Involvement of the Vestibular System in a Child’s Cognitive and Motor Development
NCT05322538Not specifiedNOT_YET_RECRUITINGMenier’s Disease - Bone Density Study
NCT05414903Not specifiedRECRUITINGReading Outcomes in Children With Vestibular Loss
NCT05622344Not specifiedRECRUITINGStableEyes With Active Neurofeedback
NCT05831618Not specifiedNOT_YET_RECRUITINGNew Rehabilitation Protocol for Patients With PPPD
NCT05942781Not specifiedACTIVE_NOT_RECRUITINGConcurrent Vestibular Activation and Postural Training Using Virtual Reality
NCT06177132Not specifiedNOT_YET_RECRUITINGVestibular Infant Screening - Rehabilitation
NCT06229704Not specifiedRECRUITINGVestibular and Postural Function in Children Suspected of Balance Disorders
NCT06229717Not specifiedRECRUITINGVestibular and Postural Function in an Unselected Group of Children With Sensorineural Hearing Loss
NCT06683417Not specifiedNOT_YET_RECRUITINGEffectiveness of VestAid App
NCT06688578Not specifiedRECRUITINGTesting Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait
NCT07079488Not specifiedENROLLING_BY_INVITATIONVestibular Function and Motor Development in Small Children
NCT07238387Not specifiedNOT_YET_RECRUITINGEvaluation of Nystagmus Examination Using Wearable AR Glasses in Vertigo Patients
NCT07267910Not specifiedNOT_YET_RECRUITINGMeasuring Vestibular Organ Function With Weak Alternating Current Stimulation
NCT07559162Not specifiedNOT_YET_RECRUITINGAi Chi-Based Rehabilitation for Peripheral Unilateral Vestibular Dysfunction
NCT07575074Not specifiedNOT_YET_RECRUITINGOKT With Gaze and Postural Stabilization on Vertigo, MS and QOL in VBH
NCT01399671Not specifiedCOMPLETEDStudy of the Effectiveness of Vestibular Stimulation as a Coadjuvant Treatment in Major Depression
NCT02072460Not specifiedUNKNOWNVestibular and Multisensory Influence on Bodily and Spatial Representations
NCT02735096Not specifiedTERMINATEDTesting an Intraoral Electronic Balance Aid for Vestibular Imbalance
NCT02746770Not specifiedUNKNOWNPhysiotherapy in Vestibular Disorders
NCT03163901Not specifiedCOMPLETEDThe Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury
NCT03330262Not specifiedCOMPLETEDHead-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability
NCT03417596Not specifiedCOMPLETEDVestibular Rehabilitation in Patients With Vestibular Migraine
NCT03421847Not specifiedCOMPLETEDStudy of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects.
NCT03431506Not specifiedUNKNOWNVestibular Function and Vestibular Rehabilitation in SSHL With Vertigo
NCT03446677Not specifiedCOMPLETEDPostural Stability Deficiencies in Asymptomatic Individuals With HIV
NCT03555370Not specifiedCOMPLETEDVestibular Treatment in Adolescents Following Sport Related Concussion
NCT03579186Not specifiedWITHDRAWNOKS for Gait Instability
NCT03600324Not specifiedCOMPLETEDRandomized Controlled Trial for Vestibular Treatment in Concussion
NCT03624283Not specifiedUNKNOWNInterventions for Residual Dizziness After Successful Repositioning Maneuvers in Patients With BPPV
NCT03677661Not specifiedCOMPLETEDCervico-vestibular Rehabilitation for Mild Traumatic Brain Injury
NCT03690817Not specifiedUNKNOWNHearing Loss, Vestibular Loss and Cognitive Performance
NCT03826056Not specifiedCOMPLETEDNeurology Inpatient Clinical Education Trial
NCT03915353Not specifiedCOMPLETEDEvaluation Of Vestibular Functions and Balance in Edirne Band Musicians
NCT03951584Not specifiedCOMPLETEDPrognosis of Vestibular Dysfunction in Patients With Idiopathic Sudden Sensorineural Hearing Loss
NCT03952936Not specifiedCOMPLETEDVestibular Rehabilitation for Chronic Central Vestibular Deficits: A Case Study
NCT03957044Not specifiedCOMPLETEDthe Effect of Vestibular Rehabilitation in Autistic Children
NCT04053829Not specifiedUNKNOWNFeasibility and Acceptability of HOLOBalance Compared to Standard Care in Older Adults at Risk for Falls
NCT04196933Not specifiedWITHDRAWNAnalysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BETAHISTINE41
INDOPROFEN41
CHEMBL44323202
BETAHISTINE MESILATE-11